ClinicalTrials.gg
Active, not recruitingNCT07037433MARITIME-CVUpdated Oct 29, 2026

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

A Phase 3 interventional study of Maridebart Cafraglutide and Placebo in Atherosclerotic Cardiovascular Disease, Overweight and Obesity, sponsored by Amgen. Active, not recruiting at 783 sites in 36 countries. Open to participants aged 45 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Oct 29, 2026Now Active, not recruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,800
Allocation
Randomized
Ages
45 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.

Planned enrollment
13th of 328
12,800 · median 119
Started
2025
with 17 others
Phase 3
61 of 468
6 open now
Primary completion
2028-06
later than 51 of 70 live
Registered
444th of 468
by date

Among the 468 studies in Atherosclerosis with a site in United States, this one is the 13th largest by planned enrollment of the 328 interventional ones that give a count, is one of 18 that started in 2025, is one of 61 in phase 3, reaches primary completion later than 51 of the 70 other live ones, and was the 444th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.

This study: 45 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 468 studies in Atherosclerosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease
  • Overweight
  • Obesity

Keywords

  • Atherosclerotic Cardiovascular Disease
  • Overweight
  • Obesity
  • Maridebart cafraglutide
  • AMG 133
  • MariTide
04

Who can participate

Ages eligible
45 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 45 years at screening.
  • of ≥ 27.0 kg/m\^2 at screening.
  • History of Atherosclerotic Cardiovascular Disease (ASCVD) with a documented history of at least one of the following:

    • Prior MI (presumed atherothrombotic event due to plaque rupture/erosion).
    • Prior ischemic stroke (presumed due to atherosclerosis; may include ischemic stroke with hemorrhagic transformation).
    • Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) \< 0.9 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease.

Exclusion criteria

Exclusion Criteria

  • History of any of the following within 60 days before screening or between screening and randomization: MI, hospitalization for unstable angina, arterial revascularization (eg, coronary, cerebrovascular or peripheral) major cardiovascular surgery, stroke, or (TIA).
  • (NYHA) class IV HF during screening or hospitalization for HF within 60 days before screening or between screening and randomization.
  • Type 1 DM, or any other type of diabetes with the exception of T2DM or prior gestational diabetes. Participants with a history of gestational diabetes should be stratified according to their current diabetes classification.
  • For participants with T2DM (including those without a prior history of T2DM but with a ≥ 6.5% during screening):

    • HbA1c > 10.0% (86 mmol/mol) at screening.
    • History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization.
    • One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness.
    • History of proliferative diabetic retinopathy, diabetic maculopathy, severe non-proliferative diabetic retinopathy, or currently receiving or planning to receive treatment for diabetic retinopathy and/or diabetic macular edema.
  • Use of any glucagon-like peptide-1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days before randomization or planned use during the conduct of the trial.
  • History of chronic pancreatitis or history of acute pancreatitis in the 180 days before screening or between screening and randomization.
  • Family (first-degree relative[s]), or personal history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN-2).
  • Calcitonin ≥ 50 ng/L (pg/mL) at screening.
  • Acute or chronic hepatitis; signs and symptoms of any liver disease other than metabolic dysfunction-associated steatotic liver disease, or (ALT) > 3.0 x the (ULN) during screening, or total (TBL) > 1.8 x ULN during screening (for participants with a known diagnosis of Gilbert syndrome, direct bilirubin should be used instead of TBL).
  • History of within the last 5 years before screening or between screening and randomization (except for the following treated with curative intent: non-melanoma skin cancer, breast ductal carcinoma in situ, cervical carcinoma in situ, or prostate cancer in situ).
  • Participants of planning to become pregnant while on study or unwilling to use protocol-specified methods of during treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12,800 participants (estimated)

Study arms

  • Experimental
    Maridebart Cafraglutide

    Participants will receive maridebart cafraglutide subcutaneously (SC).

    Drug: Maridebart Cafraglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC.

    Drug: Placebo

Interventions

  • Maridebart cafraglutide will be administered SC.

    Also known as: AMG 133, MariTide

  • DrugPlacebo

    Placebo will be administered SC.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])

    Time frame: Up to approximately 35 months

  2. Time to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, MI, Ischemic Stroke, Coronary Revascularization, or Heart Failure (HF) Event (5-point MACE)

    Time frame: Up to approximately 35 months

Secondary outcomes

  1. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke, or HF Event

    Time frame: Up to approximately 35 months

  2. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke or Coronary Revascularization

    Time frame: Up to approximately 35 months

  3. Time to First MI

    Time frame: Up to approximately 35 months

  4. Time to First Ischemic Stroke

    Time frame: Up to approximately 35 months

  5. Time to CV Death

    Time frame: Up to approximately 35 months

  6. Time to All-cause Death

    Time frame: Up to approximately 35 months

  7. Time to First Coronary Revascularization

    Time frame: Up to approximately 35 months

  8. Time to First HF Event

    Time frame: Up to approximately 35 months

  9. Time to First HF Event or CV Death

    Time frame: Up to approximately 35 months

  10. Time to First Unstable Angina Requiring Hospitalization

    Time frame: Up to approximately 35 months

  11. Time to First Occurrence of MI or CV Death

    Time frame: Up to approximately 35 months

  12. Time to First Occurrence of MI, Ischemic Stroke or All-cause Death

    Time frame: Up to approximately 35 months

  13. Total Major Ischemic Events (Time to First and Recurrent MI or Ischemic Stroke)

    Time frame: Up to approximately 35 months

  14. Total All-cause Hospitalizations (Time to First and Recurrent Event)

    Time frame: Up to approximately 35 months

  15. Time to Onset of Type 2 Diabetes Mellitus (T2DM) in Participants with Prediabetes at Baseline

    Time frame: Up to approximately 35 months

  16. Time to Onset of T2DM in Participants without T2DM at Baseline

    Time frame: Up to approximately 35 months

  17. Change from Baseline in Systolic Blood Pressure (SBP) at Week 72

    Time frame: Baseline and Week 72

  18. Change from Baseline in Diastolic Blood Pressure (DBP) at Week 72

    Time frame: Baseline and Week 72

  19. Change from Baseline in Body Mass Index (BMI) at Week 72

    Time frame: Baseline and Week 72

  20. Change from Baseline in Waist Circumference at Week 72

    Time frame: Baseline and Week 72

  21. Change from Baseline in Urine Albumin-to-creatinine Ratio (uACR) at Week 72

    Time frame: Baseline and Week 72

  22. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72

    Time frame: Baseline and Week 72

  23. Change from Baseline in Fasting Plasma Glucose at Week 72

    Time frame: Baseline and Week 72

  24. Percent Change from Baseline in High-sensitivity C-reactive protein (hs-CRP) at Week 72

    Time frame: Baseline and Week 72

  25. Percent Change from Baseline in Body Weight at Week 72

    Time frame: Baseline and Week 72

  26. Percent Change from Baseline in Total Cholesterol at Week 72

    Time frame: Baseline and Week 72

  27. Percent Change from Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 72

    Time frame: Baseline and Week 72

  28. Percent Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 72

    Time frame: Baseline and Week 72

  29. Percent Change from Baseline in Triglycerides (TG) at Week 72

    Time frame: Baseline and Week 72

  30. Number of Participants at Week 72 with HbA1c < 6.5% (48 mmol/mol) in Participants with T2DM at Baseline

    Time frame: Baseline and Week 72

  31. Number of Participants at Week 72 with HbA1c < 6.0% (42 mmol/mol) in Participants with T2DM at Baseline

    Time frame: Baseline and Week 72

  32. Number of Participants at Week 72 with HbA1c < 5.7% (39 mmol/mol) in Participants with T2DM at Baseline

    Time frame: Baseline and Week 72

  33. Number of Participants at Week 72 with HbA1c < 6.5% (48 mmol/mol) in Participants Without T2DM at Baseline

    Time frame: Baseline and Week 72

  34. Number of Participants at Week 72 with HbA1c < 6.0% (42 mmol/mol) in Participants Without T2DM at Baseline

    Time frame: Baseline and Week 72

  35. Number of Participants at Week 72 with HbA1c < 5.7% (39 mmol/mol) in Participants Without T2DM at Baseline

    Time frame: Baseline and Week 72

  36. Number of Participants at Week 72 with HbA1c < 5.7% (39 mmol/mol) in Participants with HbA1c ≥ 5.7% and < 6.5% at Baseline

    Time frame: Baseline and Week 72

  37. Change from Baseline in Short Form 36 Health Survey Acute Version 2 (SF-36 v2) Physical Function Domain Score at Week 48

    Time frame: Baseline and Week 48

  38. Time to First Event of a Composite Nephropathy Endpoint

    Composite endpoint consists of onset of persistent macroalbuminuria, persistent ≥ 40% reduction in estimated glomerular filtration rate (eGFR), onset of persistent eGFR \< 15 mL/min/1.73 m\^2, initiation of chronic renal replacement therapy (dialysis or transplantation), CV or renal death.

    Time frame: Up to approximately 35 months

  39. Change in eGFR (total slope) for the period from baseline to the final follow up visit

    Time frame: Baseline up to approximately 35 months

  40. Change in eGFR (chronic slope) for the period from 4 months to the final follow-up visit

    Time frame: From 4 months up to approximately 35 months

  41. Time to First Occurrence of a Major Adverse Limb Event (MALE) Defined as Acute Limb Ischemia, Urgent Peripheral Revascularization, Major Amputation Due to a Vascular Etiology or Chronic Limb-threatening Ischemia Requiring Revascularization

    Time frame: Up to approximately 35 months

  42. Total Arterial (Coronary, Cerebrovascular, and Peripheral) Revascularization Procedures (Time to First and Recurrent Event)

    Time frame: Up to approximately 35 months

  43. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke, MALE, or Arterial Revascularization

    Time frame: Up to approximately 35 months

  44. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke, or Acute Limb Ischemia

    Time frame: Up to approximately 35 months

  45. Time to First Occurrence of a Composite Endpoint Consisting of CV Death, MI, Ischemic Stroke, Acute Limb Ischemia, or Urgent Arterial Revascularization Procedure (Coronary, Cerebrovascular or Peripheral)

    Time frame: Up to approximately 35 months

  46. Number of Participants with Treatment-emergent Adverse Events

    Time frame: Up to approximately 35 months

  47. Number of Participants with Serious Adverse Events

    Time frame: Up to approximately 35 months

  48. Plasma Concentration of Maridebart Cafraglutide at Week 72

    Time frame: Week 72

07

Study locations

783 sites

Showing the first 100 of 783 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2028, 35 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 35 months is close to that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 25, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Sep 29, 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Sites
3 sites added, 3 sites removed. 9 sites changed recruiting status (9 now terminated)
Show 9 sites
  • Velocity Clinical Research- Los Angeles · La Mesa, United StatesCompleted→Terminated
  • Monroe Biomedical Research · Louisville, United StatesCompleted→Terminated
  • Alliance for Multispecialty Research - Norman · Norman, United StatesCompleted→Terminated
  • Military Medical Academy - Multiprofile Hospital for Active Treatment Sofia · Sofia, BulgariaCompleted→Terminated
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia · Foggia, ItalyRecruiting→Terminated
  • Azienda Sanitaria Locale Abruzzo 1 Avezzano, Sulmona e L'Aquila - Ospedale regionale San Salvatore · L’Aquila, ItalyRecruiting→Terminated
  • Bethesda Diabetes Research Center · Hoogeveen, NetherlandsCompleted→Terminated
  • Koc Universitesi Hastanesi · Istanbul, Turkey (Türkiye)Recruiting→Terminated
  • Otto von Guericke Universitaet Magdeburg · Magdeburg, GermanyRecruiting→Terminated
Show 3 added (1 Hungary, 1 United States, 1 Slovakia)
  • MedKontroll Egeszsegkozpont · Budapest, Hungary
  • Huntsville Clinical Research, LLC · Huntsville, United States
  • Poliklinika Nemocnicna as · Malacky, Slovakia
Show 3 removed
  • Zugloi Egeszsegugyi Szolgalat · Budapest, Hungary
  • Heart Center Research LLC · Huntsville, United States
  • Nemocnicna as · Malacky, Slovakia
across 3 updates, Oct 5, 2026 – Oct 29, 2026
Show all 3 updates
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Slovakia)
    • Huntsville Clinical Research, LLC · Huntsville, United States
    • Poliklinika Nemocnicna as · Malacky, Slovakia
    Show 2 removed
    • Heart Center Research LLC · Huntsville, United States
    • Nemocnicna as · Malacky, Slovakia
    + 1 other change: contact details
  2. Oct 8, 2026
    1 site added, 1 site removed. Otto von Guericke Universitaet Magdeburg is now Terminated
    Show site
    • MedKontroll Egeszsegkozpont · Budapest, Hungary
    Show 1 removed
    • Zugloi Egeszsegugyi Szolgalat · Budapest, Hungary
    + 1 other change: verification date
  3. Oct 5, 2026
    8 sites changed recruiting status (8 now terminated)
    Show 8 sites
    • Velocity Clinical Research- Los Angeles · La Mesa, United StatesCompleted→Terminated
    • Monroe Biomedical Research · Louisville, United StatesCompleted→Terminated
    • Alliance for Multispecialty Research - Norman · Norman, United StatesCompleted→Terminated
    • Military Medical Academy - Multiprofile Hospital for Active Treatment Sofia · Sofia, BulgariaCompleted→Terminated
    • Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia · Foggia, ItalyRecruiting→Terminated
    • Azienda Sanitaria Locale Abruzzo 1 Avezzano, Sulmona e L'Aquila - Ospedale regionale San Salvatore · L’Aquila, ItalyRecruiting→Terminated
    • Bethesda Diabetes Research Center · Hoogeveen, NetherlandsCompleted→Terminated
    • Koc Universitesi Hastanesi · Istanbul, Turkey (Türkiye)Recruiting→Terminated

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07037433
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jul 25, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Sep 29, 2030 (estimated)
Last update
Oct 29, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion